Head to Head Review: Indivior (OTCMKTS:INVVY) vs. Iterum Therapeutics (NASDAQ:ITRM)

Iterum Therapeutics (NASDAQ:ITRM) and Indivior (OTCMKTS:INVVY) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Iterum Therapeutics and Indivior’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Indivior	N/A	N/A	N/A

Insider & Institutional Ownership

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Indivior shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Iterum Therapeutics and Indivior, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1	2	0	0	1.67
Indivior	0	0	1	0	3.00

Indivior has a consensus price target of $50.00, suggesting a potential upside of 128.88%. Given Indivior’s stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Iterum Therapeutics.

Earnings and Valuation

This table compares Iterum Therapeutics and Indivior”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04
Indivior	$791.00 million	3.81	$205.00 million	$1.05	20.81

Indivior has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Summary

Indivior beats Iterum Therapeutics on 8 of the 12 factors compared between the two stocks.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

About Indivior

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.